A primary thymic adenocarcinoma with two components that traced distinct evolutionary trajectories

Even though it is a rare subtype, identifying the genetic features of thymic adenocarcinoma is valuable for a multifaceted understanding of thymic epithelial tumors. We experienced a female patient with thymic adenocarcinoma associated with thymic cysts. The tumor consisted of a solid whitish lesion (lesion‐1) and a large cystic lesion with small papillary nodules (lesion‐2). Microscopically, lesion‐1 exhibited poorly differentiated adenocarcinoma accompanying numerous inflammatory cell infiltrates, and lesion‐2 (the nodules within the cystic lesion) exhibited enteric‐type adenocarcinoma. Consistent with the histological difference, whole‐exome sequencing revealed that these two components exhibited distinct genetic features, except for only a few shared mutations, including CDKN2A truncation. Lesion‐1 exhibited microsatellite instability‐high signature with high mutation burden, for which immune checkpoint inhibitors might apply; and lesion‐2 exhibited whole‐genome doubling with KRAS hotspot mutation. Our case presents novel genetic features of thymic adenocarcinoma and demonstrates that distinct mutational processes can be operative within a single tumor.

[1]  S. Ogawa,et al.  Clonal expansion in non-cancer tissues , 2021, Nature Reviews Cancer.

[2]  G. Ott,et al.  A tuft cell-like signature is highly prevalent in thymic squamous cell carcinoma and delineates new molecular subsets among the major lung cancer histotypes. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Joshua D. Campbell,et al.  Whole genome doubling confers unique genetic vulnerabilities on tumor cells , 2020, Nature.

[4]  Nicolai J. Birkbak,et al.  Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution , 2020, Nature Genetics.

[5]  J. Ross,et al.  Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Benjamin J. Raphael,et al.  The Integrated Genomic Landscape of Thymic Epithelial Tumors. , 2018, Cancer cell.

[7]  D. Fujimoto,et al.  KRAS mutation-positive mucinous adenocarcinoma originating in the thymus. , 2017, Journal of thoracic disease.

[8]  Se-Hoon Lee,et al.  Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma , 2017, BMC Cancer.

[9]  Jaime Rodriguez-Canales,et al.  A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors , 2014, Nature Genetics.

[10]  R. Siebert,et al.  Primary adenocarcinoma of the thymus: an immunohistochemical and molecular study with review of the literature , 2013, BMC Clinical Pathology.

[11]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[12]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[13]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[14]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[15]  I. Nash,et al.  Intratumor heterogeneity and branched evolution. , 2012, The New England journal of medicine.

[16]  E. Somers International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.